Immune Response Testing of Electrospun Polymers: An Important Consideration in the Evaluation of Biomaterials
Source abstract
Abstract
Due primarily to cell sourcing issues, many in the field of tissue engineering have opted to create scaffolds that promote in situ regeneration, using the body as both the bioreactor and the cell source for the remodeling of scaffolds, resulting in the formation of native tissue. This practice raises many concerns, with the body's immune response to such an implant often being neglected as a potential problem in preliminary design and biocompatibility testing. More importantly, what happens over time in terms of the immune responses as the biodegradable scaffold structures being utilized to promote in situ regeneration begin to degrade, forming structural fragments and degradation products? In summary, immune response evaluations are critical considerations that must be conducted when evaluating bioresorbable scaffolds. In addition, it is essential that these evaluations analyze materials for their potential dose-response and time-course effects on the various components of innate and acquired immunity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · RNA Interference and Gene Delivery · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia USA
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia USA
References (58)
Show source-provided references
1. 10.1016/0142-9612(92)90010-L10.1016/0142-9612(92)90010-L ↗
2. 10.3109/0882013980907089610.3109/08820139809070896 ↗
3. 10.3109/0148054940901786010.3109/01480549409017860 ↗
4. 10.3109/0148054940901786110.3109/01480549409017861 ↗
5. Klykken PC · Current Topics in Microbiology and Immunology. · 1996 · 210 · 113
6. 10.1006/clin.1998.456710.1006/clin.1998.4567 ↗
7. 10.3109/0148054860899828210.3109/01480548608998282 ↗
8. 10.3109/0148054850904106210.3109/01480548509041062 ↗
9. 10.1177/09603271950140013510.1177/096032719501400135 ↗
10. Brown EJ · 2003 · 1105
11. 10.1016/0142-9612(84)90060-710.1016/0142-9612(84)90060-7 ↗
12. Mitchell RN · 2004 · 304
13. 10.1002/jbm.82021031010.1002/jbm.820210310 ↗
14. 10.1002/jbm.82023080810.1002/jbm.820230808 ↗
15. 10.1002/jbm.82022080510.1002/jbm.820220805 ↗
16. 10.1016/0142-9612(89)90023-910.1016/0142-9612(89)90023-9 ↗
17. 10.1002/jbm.82023090410.1002/jbm.820230904 ↗
18. 10.1002/jbm.82026070310.1002/jbm.820260703 ↗
19. 10.1006/cyto.2002.104810.1006/cyto.2002.1048 ↗
20. 10.3109/0894193940901535710.3109/08941939409015357 ↗
21. 10.1016/0741-5214(89)90478-310.1016/0741-5214(89)90478-3 ↗
22. Greisler H. · ASAIO Trans. · 1988 · 34 · 1051
23. 10.1016/0008-8749(86)90032-810.1016/0008-8749(86)90032-8 ↗
24. 10.1002/jbm.b.3009610.1002/jbm.b.30096 ↗
25. 10.1016/0008-8749(84)90019-410.1016/0008-8749(84)90019-4 ↗
26. 10.1002/(SICI)1097-4636(19980305)39:3<398::AID-JBM8>3.0.CO;2-E10.1002/(SICI)1097-4636(19980305)39:3<398::AID-JBM8>3.0.CO;2-E ↗
27. 10.1002/1097-4636(200102)54:2<234::AID-JBM10>3.0.CO;2-S10.1002/1097-4636(200102)54:2<234::AID-JBM10>3.0.CO;2-S ↗
28. 10.1002/(SICI)1097-4636(200005)50:2<259::AID-JBM21>3.0.CO;2-B10.1002/(SICI)1097-4636(200005)50:2<259::AID-JBM21>3.0.CO;2-B ↗
29. Thomas AH · Exp Biol Med (Maywood). · 2007 · 232 · 406
30. Schwarcz TH · Curr Surg. · 1987 · 44 · 18
31. 10.1088/1748-6041/1/2/00410.1088/1748-6041/1/2/004 ↗
32. Barrows TH · 1991 · 243
33. 10.1007/s10856-006-0185-810.1007/s10856-006-0185-8 ↗
34. 10.1016/0142-9612(95)93852-510.1016/0142-9612(95)93852-5 ↗
35. 10.1016/j.actbio.2004.09.00310.1016/j.actbio.2004.09.003 ↗
36. 10.1021/bk-2006-0918.ch01410.1021/bk-2006-0918.ch014 ↗
37. 10.1002/jbm.b.3010510.1002/jbm.b.30105 ↗
38. 10.1016/S0168-3659(02)00041-X10.1016/S0168-3659(02)00041-X ↗
39. 10.1177/15589250060010020210.1177/155892500600100202 ↗
40. 10.2741/131310.2741/1313 ↗
41. 10.1177/088391150301800200310.1177/0883911503018002003 ↗
42. 10.1021/bm015533u10.1021/bm015533u ↗
43. 10.1021/nl025866c10.1021/nl025866c ↗
44. Barnes CP · International Journal of Electrospun Nanofibers and Applications. · 2007 · 1 · 73
45. Smith MJ · Acta Biomater.
46. 10.1002/jbm.a.1052510.1002/jbm.a.10525 ↗
47. 10.1002/1097-4636(200010)52:1<231::AID-JBM29>3.0.CO;2-E10.1002/1097-4636(200010)52:1<231::AID-JBM29>3.0.CO;2-E ↗
48. 10.1016/0272-0590(88)90247-310.1016/0272-0590(88)90247-3 ↗
49. 10.1081/DCT-10010012710.1081/DCT-100100127 ↗
50. 10.1126/science.153.3739.100410.1126/science.153.3739.1004 ↗
51. 10.1111/j.1550-7408.2006.00158.x10.1111/j.1550-7408.2006.00158.x ↗
52. 10.1081/DCT-10010260610.1081/DCT-100102606 ↗
53. Reynolds CW · J Immunol. · 1981 · 126 · 158110.4049/jimmunol.126.4.1581 ↗
54. 10.1006/taap.2002.941810.1006/taap.2002.9418 ↗
55. 10.1016/0272-0590(92)90047-L10.1016/0272-0590(92)90047-L ↗
56. Holsapple MP · J Pharmacol Exp Ther. · 1983 · 227 · 13010.1016/S0022-3565(25)21923-1 ↗
57. 10.1006/faat.1993.111610.1006/faat.1993.1116 ↗
58. 10.1006/faat.1993.107410.1006/faat.1993.1074 ↗